...Happy to, and thank you for having us, David. Appreciate it. I think you did a really nice job of explaining that Ionis is the leader in RNA-based therapeutics and particularly the pioneer in antisense technology. And we've created a very deep and late-stage, frankly, pipeline from that as well as a very prolific drug discovery engine. Today, we're focused on really 3 strategic objectives. The first is bringing as many medicines forward to the market as we possibly can. Second, to -- we've really evolved to the place where we now want to add excellence in commercialization to our renowned excellence in research and development. So we would like to be commercializing medicines ourselves and are building capabilities and advancing towards that with a number of our wholly owned medicines. And then third, we have a very important strategic objective to continue to advance our technology and extend the reach of the technology so that we can address more and more tissue types and improve even...
